BioCardia Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

BioCardia şirketinin toplam hissedar öz sermayesi $-2.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.9M ve $4.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.42m
Eşitlik	-US$1.96m
Toplam yükümlülükler	US$4.85m
Toplam varlıklar	US$2.89m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6JU0 negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: 6JU0 şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6JU0 borçsuzdur.

Borcun Azaltılması: 6JU0 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6JU0 son raporlanan serbest nakit akışına göre 2 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 6JU0 serbest nakit akışı tahminlerine göre 2 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

BioCardia Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family

BioCardia, Inc. Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.55 loss per share (vs US$0.67 loss in FY 2022)

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 3Q 2022)

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

New major risk - Revenue size

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.14 loss in 2Q 2022)

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

Insider recently bought €164k worth of stock

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 1Q 2022)

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.75 loss in FY 2021)

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2021)

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2021)

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2021)

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings released: US$0.75 loss per share (vs US$1.48 loss in FY 2020)

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia®, Inc Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.30 loss in 3Q 2020)

BioCardia, Inc. Announces Data from Its CardiAMP® Cell Therapy Heart Failure Pivotal Trial to Present at the Heart Failure Society of America Annual Meeting 2021 on September 11, 2021

Second quarter 2021 earnings released: US$0.20 loss per share (vs US$0.46 loss in 2Q 2020)

Biocardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal Cardiamp Cell Therapy Heart Failure Study as Designed

BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.67 loss in 1Q 2020)

Full year 2020 earnings released: US$1.48 loss per share (vs US$2.61 loss in FY 2019)

Biocardia, Inc. Enters into Agreement with Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates